Nexavar - Newsfeeds

Jennerex Appoints Lara Longpre to Chief Operating Officer: and a Phase 2 study in combination with sorafenib. Prior, published studies designed to establish dose levels and the safety profile of JX-594 have shown its ability to selectively target a variety of common cancer ...
Extracerebral metastases determine the outcome of patients with brain metastases ...: sorafenib, temsirolimus or bevacizumab. The median PFS was 8.7 months (95% CI 5.1 - 12.3) and 11.4 months (95% CI 8.7 - 14.1) for BM-patients and non-BM-patients, respectively (p=0.232). The median overall survival ...
AVEO Pharmaceuticals, Inc. to Present at Several Upcoming Investment Conferences: randomized Phase 3 clinical trial called TIVO-1 comparing tivozanib to sorafenib in advanced kidney cancer, as well as additional clinical studies in other solid tumor types. AVEO’s proprietary, integrated cancer ...
The Cancer Chronicles- A Re-Cap from Last year. I hope it may help someone.: but you’ve only been on the Nexavar for a few weeks, but are now down to less than 2 weeks going by the original time frame given. Fighting over increasing the dosage to the maxium you are allowed because they are ...
Pipeline Review: Bristol-Myers Squibb's 5 Keys to Success: It's the same strategy that Pfizer followed for Sutent and that Bayer and Onyx Pharmaceuticals followed for Nexavar. All three drugs inhibit growth factor receptors required for blood vessel growth. No blood,
Cocktails Are Next For Cancer-Drug Makers: such as Roche's Avastin and Bayer's Nexavar. Yet Roche's Mellman says combinations of pre-approved treatments are "old school," and that the real potential for drugmakers will be in the next generation of targeted ...
Penn study makes breakthrough in shrinking tumors of terminal melanoma patients: Flaherty had shown that Nexavar, an anti-BRAF drug approved to treat kidney cancer, did not work against melanoma, even when combined with standard chemotherapy. Skeptics doubted that the BRAF gene was a good target ...
Owing to Increased Access to Medical Care and a Growing Drug-Treated Population ...: ... population and a rising number of higher-income HCC patients requesting the more-efficacious and costly Western brands of targeted agents such as Bayer's Nexavar. The new Emerging Markets report entitled Liver ...
Onyx Pockets $59M Upfront From Japanese Partner, to Market Myeloma Drugs: has been seeking for some time to diversify itself beyond its current position as a one-drug company driven by sorafenib (Nexavar). That drug, approved by the FDA for kidney and liver cancers, generated $843 million ...
Aveo Pharma Stock Jumps 40 Percent in A Week, CEO Notes Progress in Pivotal Kidney Cancer Trial: the firm is testing its drug head-to-head with Bayer’s and Onyx Pharmaceuticals’s sorafenib (Nexavar). Aveo says that patients who took its drug in its mid-stage study, which included 272 participants,

Onyx snags $339M Japan deal for PhIII cancer med: capable of earning the same big bucks as Nexavar. In the Phase IIb data, carfilzomib showed promising response rates and good tolerability with a three-drug combination in patients with relapsed or refractory myeloma.
Onyx Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference: is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in ...
The Daily Scan: Signaling by the mutant proteins was resistant to the small-molecule inhibitor sorafenib, but sorafenib still inhibited the growth of tumors driven by the mutant protein," the authors write. Iddo Friedberg at Byte Size ...
Thyroid Cancer: 1st Treatment in 30 Years: NEW TREATMENT: Sorafenib is an oral drug that is geared to stop and shrink tumors. Currently, sorafenib is FDA approved and being used to treat advanced renal cell carcinoma, a type of cancer that begins in the kidneys.
Hope for Melbourne liver cancer patients: They are part of a Melbourne-led international human trial of SIRT, used in conjunction with the chemotherapy drug sorafenib. Start of sidebar. Skip to end of sidebar. End of sidebar. Return to start of sidebar.
Combination of SIR-Spheres and Sorafenib confers survival benefit for patients with inoperable HCC: Polly Klitz wrote: I have a male relative with geno type 1 with hep C… [More] Teva Pharmaceutical launches Gianvi Tablets (2) Robbie wrote: The generic is 20 dollars cheaper here without ins… [More] Race differences ...
Study Reveals Survival Benefit for Patients with Inoperable Hepatocellular Carcinoma (HCC)...: BusinessWire - A unique combination of liver targeted radioactive microspheres (SIR-Spheres) and a standard-of-care systemic agent (Sorafenib) appears to confer a survival benefit for patients with inoperable primary ...
Study: Combo Melanoma Therapy Ineffective: With this study, we learned that the addition of sorafenib, a molecular inhibitor, to a traditional chemotherapy regimen does not improve patient survival." The 34-month, phase III trial involved 823 patients from seven ...
Cancer treatment pioneered in Melbourne being hailed as a global lifesaver: These treatments are part of a Melbourne-led international human trial of SIRT, used in conjunction with the chemotherapy drug sorafenib. For the procedure, tiny radioactive beads - about one-third the width of a human ...
Onyx Pharmaceuticals to Participate in Goldman Sachs 2010 Healthcare Conference: is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Sign up for the free Simply Best Penny Stocks ...

Want to contact a District of Columbia Nexavar attorney? ...Get a free case evaluation from one of our District of Columbia Nexavar attorneys now.

Content provided by MSN. LegalView is not responsible for the accuracy of the information provided above.

Pages: 1 2 3 Next

Need A Nexavar Attorney?

First Name Last Name Email Address State

Legal Issue

DrugWatch: Nexavar Click to select a Legal Issue

Has Your Health Been Negatively Affected?

Please Describe the Injury

close this window

Nexavar Information

Click to View Our Legal Resources

Want to contact a District of Columbia Nexavar attorney? ...Get a free case evaluation from one of our District of Columbia Nexavar attorneys now.

LegalView.info is sponsored by law firms with offices in many states. This website contains information created by others or supplied through open forums; the sponsoring law firms are not responsible for the accuracy of this information. Your access to this site does not constitute a legal attorney-client relationship. The choice of a lawyer is an important decision and should not be based solely upon advertisements. To access important information concerning the sponsors and their commitment to the ethical practice of law, click here.

The participating law firms are as follows: Anapol Schwartz (Philadelphia, Pennsylvania; Cherry Hill, New Jersey; Media, Pennsylvania; Reading, Pennsylvania; Wheeling, WV). Cohen, Placitella & Roth (Red Bank, New Jersey; Philadelphia, Pennsylvania). J. F. Humphreys (Charleston, West Virginia). Lopez McHugh (Newport Beach, California; Philadelphia, PA; and Moorestown, NJ). Click here for more information about these law firms.

Some of our partner firms do not accept some types of cases. For details on these case exceptions, click here.

20120223-062613

Close (x)

Looking for an Attorney?

Please type your question:

First Name:
Last Name:
E-mail:
Phone Number *
() -

State * Legal Issue *

DrugWatch: Nexavar Click to select a Legal Issue

Close (x)

Find Legal Help for Your Nexavar Case - Submit Your Information Below

Do you need legal assistance with your Nexavar case?
LegalView may be able to help.

Submit your information below for a free, no-cost evaluation.

We'll submit your information to one of our partner firms.
LegalView's partners represent clients throughout the United States, for a very wide range of legal issues. Submit your information now, to see if one of LegalView's partners can help!

* Indicates Required Fields

First name *

Last name *

Email Address *

Phone Number *
() -

State *

Legal Issue * DrugWatch: Nexavar Change

Was There an Injury?

Please Describe The Injury

Please State Your Question *

DISCLAIMER and STATEMENT OF NON-CONFIDENTIALITY

By submitting this form, you agree that completing the above is not intended to create an attorney-client relationship.

Disclosure

Legal WebTV Network LLC, LegalView.com, and LegalWebMedia.com are group advertising sponsored by the attorneys identified here. It is not a lawyer referral service. If you submit information on this website, LegalWebMedia.com will submit your information to the law firms that pay for this group advertising and to respond to your requests for information concerning legal services in their assigned local areas. If there is no sponsoring firm in your state, your inquiry will be submitted to one of the sponsoring law firms on a predetermined, rotating basis. If the sponsoring law firm accepts your case, it will associate with licensed attorneys practicing in your state, if required; the sponsoring law firm may also contact other law firms to see if they may be able to assist.

The information provided by the LegalView.com and LegalWebMedia.com websites is for advertising and informational purposes and should not be considered as legal advice from the sponsoring attorneys. The websites contain general information and may not reflect current legal developments, verdicts, or settlements. LegalView.com contains information created by others or supplied through open forums; the sponsoring law firms are not responsible for the accuracy of this information. Any person viewing or receiving information from these websites should not act or refrain from acting on the basis of any such information without first seeking appropriate legal advice from an attorney in your area. Legal WebTV Network, LLC expressly disclaims any liability with respect to actions taken or not taken by the recipient based on any or all of the information or contents contained in these websites.

Any information sent to Legal WebTV Network LLC through this website is done using standard Web encryption techology. LegalView.com will exercise all reasonable care, within technological limits, to protect the confidentiality of any information submitted via Internet e-mail or through this website. By accessing this website, you may be seeking an attorney to represent you or legal advice. However, none of the sponsoring attorneys represent you yet.

The choice of a lawyer is an important decision and should not be based solely upon advertisements.

Any transmission of information, whether via Internet e-mail or through the website, is solely for evaluation purposes by the sponsoring law firms and their associates. The transmission of any information to any attorney sponsoring advertising on LegalView.com or LegalWebMedia.com does not create an attorney-client relationship between the sender and any recipient. An attorney-client relationship can only be created by a written, signed-fee agreement entered into with an attorney. The sponsoring attorneys will treat your information as a confidential communication for the purpose of obtaining legal services or legal advice.

For more information about the sponsoring law firms, please click here.

This form is secure and encrypted. More information about secure forms and your privacy here.